# Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

> **NCT00486421** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 22 (estimated)

## Conditions studied

- Nonneoplastic Condition

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00486421
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-11
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2014-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486421, "Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00486421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*